STADA Arzneimittel (ETR:SAZ) received a €74.40 ($88.57) price objective from investment analysts at Nord/LB in a research note issued to investors on Wednesday. The brokerage currently has a “sell” rating on the stock. Nord/LB’s price objective indicates a potential downside of 15.02% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on the company. Warburg Research set a €74.40 ($88.57) price objective on STADA Arzneimittel and gave the stock a “sell” rating in a research note on Tuesday, September 5th. Independent Research set a €82.00 ($97.62) price objective on STADA Arzneimittel and gave the stock a “neutral” rating in a research note on Friday, November 10th. S&P Global set a €74.40 ($88.57) price objective on STADA Arzneimittel and gave the stock a “sell” rating in a research note on Friday, November 10th. Finally, Commerzbank set a €66.25 ($78.87) price objective on STADA Arzneimittel and gave the stock a “sell” rating in a research note on Tuesday, August 22nd. Four analysts have rated the stock with a sell rating and two have issued a hold rating to the stock. The stock presently has a consensus rating of “Sell” and an average price target of €74.08 ($88.18).

Shares of STADA Arzneimittel (SAZ) opened at €87.55 ($104.23) on Wednesday. STADA Arzneimittel has a 1-year low of €46.31 ($55.13) and a 1-year high of €83.91 ($99.89).

ILLEGAL ACTIVITY WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.watchlistnews.com/nordlb-reiterates-74-40-price-target-for-stada-arzneimittel-saz/1774606.html.

STADA Arzneimittel Company Profile

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Analyst Recommendations for STADA Arzneimittel (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.